Development of New Diffuse Large B Cell Lymphoma Mouse Models.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with high rates of refractory or relapsed disease.
• Current treatment options have limited efficacy, necessitating the development of novel therapeutic strategies.
• Preclinical models are crucial for evaluating new treatments, but existing xenograft models often fail to fully recapitulate human DLBCL.

Purpose of the Study:

• To develop an accessible xenograft mouse model that better represents human Diffuse Large B Cell Lymphoma (DLBCL) for preclinical research.
• To assess the engraftment and progression of DLBCL cell lines in humanized NSG mice expressing human IL6.

Main Methods:

• Generated two human DLBCL cell lines (U2932 and VAL) expressing Luciferase (Luc) and EGFP.
• Injected these cell lines intravenously into humanized NSG mice engineered to express human IL6 (NSG-IL6).
• Monitored tumor growth, organ-specific engraftment, and progression, and evaluated cell proliferation in IL6-conditioned media.

Main Results:

• NSG-IL6 mice showed high permissiveness for DLBCL cell growth, with systemic engraftment rates of 75% (U2932) and 82% (VAL) by week two.
• DLBCL cells initially engrafted and expanded in the spleen, liver, and lung, with subsequent spread to the skeleton, ovary, and brain.
• VAL cells, associated with poor outcomes due to dual BCL2/MYC translocation, exhibited heightened proliferation and led to rapid tumor expansion and early mortality.

Conclusions:

• The developed NSG-IL6 mouse models effectively replicate the clinical features of aggressive DLBCL, demonstrating consistent tumor development patterns.
• These models overcome limitations of standard subcutaneous xenografts, offering a valuable new tool for DLBCL preclinical studies.
• The findings support the utility of NSG-IL6 mice for advancing DLBCL research and the development of novel therapeutic interventions.